Abstract
Purpose :
“Defocus Incorporated Multiple Segments” (DIMS) lenses have been proven to effectively inhibit children's myopia progression in randomized controlled trials. We performed a retrospective analysis of real-life data to evaluate the effect of DIMS lenses on axial length (AL) growth.
Methods :
Annual AL growth rates of 166 eyes treated with DIMS lenses at 12-month follow-up were compared to physiological AL growth rate using the AMMC (Age-Matched Myopia Control) system, which features three color-coded zones: green - physiological AL growth rate, yellow - moderately excessive AL growth rate and red - highly excessive AL growth rate. An AL growth rate within the green zone was considered a successful treatment. Potential differences in percentages of treatment success of various subgroups were investigated based on baseline AL and age against the percentage of treatment success of total population.
Results :
Median AL growth rates of eyes with moderate baseline AL and those of older children reached the physiological growth range. Considering all eyes, treatment success was achieved by 46%. 61% of eyes had high baseline AL. In males, eyes with high baseline AL showed treatment success in a lower proportion (25%, p<0.01), while eyes with moderate baseline AL met the treatment goal in a higher proportion (73%, p<0.01). Female eyes showed similar trend albeit without statistical significance (51% and 42%). Eyes of younger children responded successfully to treatment in a lower proportion (male: 11%, p<0.01; female: 25%, p<0.01). Eyes of older children responded successfully to treatment in a higher proportion (male: 60%, p<0.05; female: 56%, n.s.).
Conclusions :
Older children and those with moderate baseline axial lengths showed treatment success after 12 months of wearing DIMS lenses. Younger children and those with a high baseline AL and showed lower treatment success. In such cases, combination treatment (DIMS lenses &low-dose atropine) should be considered from the outset.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.